Page 3 - Pharmaceutical Companies

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

AstraZeneca vaccine: From its origin to side effects, all you need to know

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

India becoming attractive for clinical trials, says pharma industry leaders

Over the past 10 years, clinical trials in India have become easier, more accessible and accelerated, experts from the pharma sector have said as top multinationals are increasingly looking at the country as their base for clinical trials. Data from 2017 to 2023 shows that phase two and phase three clinical trials are growing at about 15 per cent to 18 per cent in India. This is primarily because of the 10 modifications done to the Drugs and Cosmetics Act of 1940, according to Badhri Srinivasan, head of Global Clinical Operations, Novartis. Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. Given where we are, given what the landscape in the international community has happened, the regulators in India are starting to move and make changes to it. Since 2013, there have been 10 modifications to that act to try to make clinical trials easier, more accelerated, more accessible, et cetera, Srinivasan said at the 18th Annua

PE firm ChrysCapital invests $70 million in formulations company La Renon

Peak XV Partners (formerly Sequoia India) has been invested in La Renon since 2015, with A91 Emerging Fund joining in 2021

Result preview: Domestic biz, easing price pressure to boost pharma margins

Hospitals and Diagnostics revenues to grow 13-15% in Q4

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Domestic drug firms to witness 8-10% revenue growth in FY25: Report

Revenue growth of leading 25 domestic drug firms is expected to moderate to 8-10 per cent in the next fiscal year, rating agency Icra said on Thursday. The revenue of the companies, which account for 60 per cent of the overall Indian pharmaceutical industry, witnessed an increase of 13-14 per cent in the current fiscal year. Following the high base of 2023-24, the revenue growth momentum from the US and Europe markets is expected to moderate to 8-10 per cent and 7-9 per cent, respectively, Icra said. The markets are expected to witness a year-on-year expansion of 18-20 per cent and 16-18 per cent, respectively, in the current fiscal year, it added. The domestic market, on the other hand, is expected to see a stable growth of 6-8 per cent, while the emerging markets may log an 8-10 per cent rise in FY25, against 16-18 per cent in FY24, the rating agency said. The revenue growth of the sample set companies in the US market in FY24 has been supported by increased new product launches

Govt's new code bars unethical marketing of drugs by pharma firms

Medical representatives barred from using 'inducement' or 'subterfuge' to access healthcare professionals

Sun Pharma recalls around 55,000 bottles of generic medication in US

Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA). As per the latest Enforcement Report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market. Mesalamine delayed-release capsules are indicated for the treatment of mild to moderate ulcerative colitis. The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc. As per the USFDA, the company has initiated the Class II recall due to "Failed Dissolution Specifications". The company initiated the Class II recall on February 5 this year. As per the USFDA, a class II recall is initiated in a situation in which the use of, or

PLI: Propelling India towards 'atmanirbhar' future in pharma and meditech

The PLI schemes in the pharma-meditech sectors have been a resounding success, and they've heralded a new era for the Indian industry

US FDA approves Eyenovia's eye drops to reduce pain: Formosa Pharma

Eyenovia acquired US commercial rights of the drug last August from Formosa

Advent PE begins merger process of Suven Pharma and Cohance Lifesciences

The merged platform will have mid-30s EBITDA margins, 30 per cent Return on Capital Employed (RoCE) and stable cash flow generation over FY20-23, the statement said

India to have largest R&D presence outside US by 2025: Bristol Myers CEO

Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16%

On a sequential basis, the company saw a 3.40 per cent decline in revenue along with Profit After Tax (PAT), which also declined by 16.77 per cent

Lupin expands global portfolio with acquisition of assets from Sanofi

The deal involves the acquisition of a portfolio of accretive established products in Europe and Canada

Zydus Lifesciences gets final FDA nod for Darunavir for HIV-1 treatment

According to market research firm IQVIA, Darunavir Tablets, 75 mg, 150 mg, 600 mg, and 800 mg had annual sales of $275 million in the US

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Rusan Pharma Invests 300 Crores in New API Facility in MP's Pithampur

New plant to produce 400 MT of APIs, creating more than 300 jobs and enhancing global supply

Cipla concludes 51.18% stake sale in Ugandan subsidiary for $25 million

The sale was executed by Cipla (EU) Limited, UK, and Meditab Holdings Limited, Mauritius, both wholly-owned subsidiaries of Cipla Limited